Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Viral Recombination

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and immunogenicity of concomitant quadrivalent meningococcus ACYW-TT and meningococcus group B vaccines.

NPJ vaccines·2026

Same author

Large outbreak of group B invasive meningococcal disease in young adults in South East England, March 2026.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026

Same author

Lower incidence and higher case fatality rates associated with invasive meningococcal disease during COVID-19 pandemic restrictions (March 2020 to July 2021) in England.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026

Same author

Meningococcal disease, meningococcal vaccines, and the recent meningococcal outbreak in Kent, UK.

The Lancet. Infectious diseases·2026

Same author

Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trial.

The Lancet. Infectious diseases·2026

Same author

Strengthening regional surveillance: MenMap Network's year 1 findings on bacterial meningitis in Jordan, Egypt, and Iraq (2023-2024).

IJID regions·2026

Same journal

Correction for Nishimori et al., “Identification of an Atypical Enzootic Bovine Leukosis in Japan by Using a Novel Classification of Bovine Leukemia Based on Immunophenotypic Analysis”

Clinical and vaccine immunology : CVI·2018

Same journal

Effect of Breastfeeding and Additional Household Children on Cytomegalovirus Seroprevalence among U.S. Children 1 to 5 Years of Age.

Clinical and vaccine immunology : CVI·2017

Same journal

Reevaluation of Positivity Cutoff Values for the Pneumococcal Urinary Antigen Detection Assay.

Clinical and vaccine immunology : CVI·2017

Same journal

The Legacy of CVI.

Clinical and vaccine immunology : CVI·2017

Same journal

Protein Structure Facilitates High-Resolution Immunological Mapping.

Clinical and vaccine immunology : CVI·2017

Same journal

Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.

Clinical and vaccine immunology : CVI·2017

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 16, 2026

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

Multivalent and Multipathogen Viral Vector Vaccines.

Katharina B Lauer^1,2, Ray Borrow^3,4, Thomas J Blanchard^3,5

¹University of Manchester, Institute of Inflammation and Repair, Manchester, United Kingdom katharina.lauer@postgrad.manchester.ac.uk.

Clinical and Vaccine Immunology : CVI

|August 19, 2016

Summary

This summary is machine-generated.

Recombinant viral vectors offer a safe and effective method for delivering antigens to stimulate immunity. Combining antigens into single vaccines (multivalent or multipathogen) can simplify immunization and combat complex diseases.

Keywords:

multidisease vaccine multipathogen vaccine multivalent vaccine polyvalent vaccine viral vector vaccine

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Related Experiment Videos

Last Updated: Mar 16, 2026

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Area of Science:

Vaccinology
Immunology
Molecular Biology

Background:

Antigen presentation is key for inducing immunity and long-lasting protection.
Recombinant viral vectors, proven safe in veterinary use, mimic natural infections to deliver foreign proteins and elicit immune responses.

Purpose of the Study:

To explore the potential of recombinant viral vectors for vaccine development.
To discuss the attributes of effective vaccine vectors.
To highlight the advantages of multivalent and multipathogen vaccines.

Main Methods:

Review of existing literature on viral vectors in vaccine applications.
Analysis of required attributes for vaccine vectors.
Discussion of strategies for combining antigens.

Main Results:

Recombinant viral vectors are suitable for delivering antigens, inducing protective antibody levels.
Key vector attributes include genomic stability, immunogenicity, safety, and scalability.
Combining antigens offers potential for multivalent, polyvalent, multidisease, and multipathogen vaccines.

Conclusions:

Recombinant viral vectors are promising tools for creating advanced vaccines.
Multivalent and multipathogen vaccines are essential for addressing complex diseases and simplifying immunization schedules.